Diamedica Therapeutics to Resume Stroke Treatment Trials After FDA Removes Hold
By Adriano Marchese
Diamedica Therapeutics is preparing to resume trials for an acute ischemic stroke treatment after the U.S. Food and Drug Administration removed a hold on the drug candidate's application.
The clinical-stage biopharmaceutical company said the FDA removed the clinical hold placed on the investigational new drug application for ReMEDy2 phase 2/3 clinical trials studying DM199, a synthetic formulation of the human tissue-1 kallikrein protein which primarily aims to enhance collateral blood flow in brain tissues affected by a stroke.
Diamedica said preparations are now underway to resume the trials of DM199 as soon as possible.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
June 21, 2023 08:54 ET (12:54 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth